化学
磷酸化
酶抑制剂
酪氨酸
蛋白酪氨酸激酶
阿尔茨海默病
对偶(语法数字)
激酶
结构-活动关系
药理学
酪氨酸激酶抑制剂
酪氨酸激酶
生物化学
疾病
信号转导
体外
内科学
癌症
艺术
文学类
医学
作者
Huanhua Chen,Xudong Gao,Xinzhu Li,Chong Yu,Wenwu Liu,Jingsong Qiu,Wenjie Liu,Hefeng Geng,Fangyuan Zheng,Hao Gong,Zihua Xu,Jing‐Ming Jia,Qingchun Zhao
标识
DOI:10.1021/acs.jmedchem.4c00483
摘要
Targeting dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) has been verified to regulate the progression of tau pathology as a promising treatment for Alzheimer’s disease (AD), while the research progress on DYRK1A inhibitors seemed to be in a bottleneck period. In this work, we identified 32 ( ZJCK-6-46 ) as the most potential DYRK1A inhibitor (IC 50 = 0.68 nM) through rational design, systematic structural optimization, and comprehensive evaluation. Compound 32 exhibited acceptable in vitro absorption, distribution, metabolism, and excretion (ADME) properties and significantly reduced the expression of p-Tau Thr212 in Tau (P301L) 293T cells and SH-SY5Y cells. Moreover, compound 32 showed favorable bioavailability, blood–brain barrier (BBB) permeability, and the potential of ameliorating cognitive dysfunction by obviously reducing the expression of phosphorylated tau and neuronal loss in vivo, which was deserved as a valuable molecular tool to reveal the role of DYRK1A in the pathogenesis of AD and to further promote the development of anti-AD drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI